Hey there, fellow cannabis enthusiasts! Today, we’re diving deep into the world of cannabis politics, specifically focusing on the FDA rescheduling saga. If you’re wondering what’s been brewing on the marijuana reform front, you’ve come to the right place. Grab your favorite strain, roll one up, and let’s get into the nitty-gritty of it all.
FDA Rescheduling: A Cannabis Conversation with an Expert
First things first, you might have heard that the FDA recently made a recommendation to reschedule cannabis. Now, before we jump the gun, let’s break down what this really means. The FDA’s suggestion is to shift marijuana from its current Schedule I status to Schedule III under the Controlled Substances Act (CSA). Sounds like progress, right?
An Unexpected Critic
Hold your horses, because here’s where the plot thickens. Enter Rep. Andy Harris, a Republican congressman from Maryland, who has made it his mission to challenge this move. Now, you might be thinking, “Wait, isn’t he from a state where medical cannabis is already legal?” You’re absolutely correct. However, Rep. Harris remains a staunch opponent of marijuana reform.
A Challenge to FDA’s “Misguided Conclusion”
In a letter to DEA Administrator Anne Milgram, Rep. Harris voiced his concerns, asserting that the FDA’s recommendation was based on a “misguided conclusion.” He pointed out that the FDA failed to consider several important factors when evaluating marijuana’s potential for abuse and harm to public health.
International Treaty Obligations
Rep. Harris also brought up the issue of international treaty obligations. He argued that the U.S. should adhere to these obligations, which, in his view, prohibit the rescheduling of cannabis. He claimed that any reclassification of marijuana outside of Schedule I or Schedule II would violate these treaties.
The UN’s Changing Stance
Interestingly, while Rep. Harris emphasizes the importance of international treaties, it’s worth noting that the United Nations (UN) has revised its global cannabis scheduling policies. Other member states, like Canada, have even legalized cannabis without facing penalties.
Flaws in FDA’s Justification
Rep. Harris didn’t stop there. He criticized the FDA for overlooking critical aspects, such as the effects of daily marijuana use and the public health risks associated with impaired driving under the influence of cannabis. He also questioned the FDA’s choice to compare marijuana to drugs like heroin, rather than considering other substances like LSD or ecstasy.
The FDA’s Data Dilemma
One of the congressman’s most significant gripes was with the FDA’s data. He argued that the FDA mischaracterized the data on marijuana’s harms, citing a lack of rigor in the studies used by the agency. This, he believed, contributed to the FDA’s misguided conclusion.
Harris’ Bifurcated Argument
Rep. Harris laid out a two-pronged argument against incremental rescheduling. He believes that such a move wouldn’t fully legalize marijuana or federally endorse state-regulated cannabis markets. Furthermore, he demanded answers from the DEA regarding its interpretation of international treaty obligations, procedural approaches, and the consideration of relevant studies.
The Not-So-Surprising Opposition
Now, you might be wondering if Rep. Harris’ stance is surprising given his track record. Spoiler alert: it’s not. He’s been a consistent opponent of marijuana reform, even going so far as to block Washington, D.C. from implementing regulated cannabis sales, despite local voters approving legalization back in 2014.
A Joint Effort Against High-Potency THC
In addition to his letter to the DEA, Rep. Harris, along with Rep. Pete Sessions and Sen. Pete Ricketts, introduced a concurrent resolution. This resolution raises concerns about high-potency THC products and calls for federal agencies to conduct further research on potential harms.
A Tug-of-War for DEA’s Attention
The letter from Rep. Harris is just one piece of the puzzle. Lawmakers from both sides of the cannabis debate are vying for the DEA’s attention. Senators Elizabeth Warren, John Fetterman, Chuck Schumer, and others have urged the DEA to go beyond rescheduling and fully remove cannabis from the CSA.
Shaping the Future of Cannabis
They argue that this move presents a rare opportunity to shape the new cannabis industry, free from corporate influence. They want federal cannabis reforms that address the harms of cannabis criminalization while acknowledging the need for regulation.
DEA’s Final Authority
Now, before you start scratching your head, it’s important to note that the DEA claims it has “final authority” over the scheduling of drugs under the CSA. They are currently reviewing all the information at hand to make their determination.
The Push for Rescheduling
Prior to the FDA’s recommendation, a coalition of 12 Democratic state attorneys general urged the DEA to move forward with federal marijuana rescheduling, citing public safety as an imperative concern. Meanwhile, the governors of six U.S. states called on the Biden administration to reschedule marijuana.
Former DEA Heads’ Opposition
Interestingly, six former DEA heads and five former White House drug czars voiced their opposition to the FDA’s recommendation. They even made claims about the relationship between drug schedules and criminal penalties, potentially exaggerating the potential impact of incremental reform.
Political Gains for President Biden
A recent poll revealed that around one-third of marijuana consumers would return to the illicit market if cannabis were rescheduled and only available as an FDA-approved prescription drug. Another survey suggested that President Joe Biden could make significant political gains if marijuana is rescheduled during his administration.
The President’s Role
President Biden has consistently highlighted his 2022 scheduling directive, along with his mass marijuana pardon. He has taken action to address federal marijuana possession offenses, signaling his support for reform. However, it’s essential to remember that he doesn’t directly control the final outcome.
Conclusion
So there you have it, a deep dive into the FDA rescheduling controversy. While the FDA’s recommendation seemed like a step in the right direction, it faces opposition from lawmakers like Rep. Andy Harris. The DEA holds the key to the fate of cannabis rescheduling, and the cannabis community eagerly awaits their decision.
And before we wrap up, a big shoutout to Kyle Jaeger for reporting on this story. Thanks to his diligent work, we’re all in the know about the latest in cannabis politics. Keep your eyes peeled for more updates, and remember to stay informed and engaged in the conversation. Cheers to the future of cannabis!
